Cargando…
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
BACKGROUND: In order to help in selecting the optimum bone-modifying agent (BMA; zoledronic acid or denosumab), we investigated the impact of the BMA on the renal function of patients with bone metastases. MATERIALS AND METHODS: The present study consisted of 118 patients who were treated with denos...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124438/ https://www.ncbi.nlm.nih.gov/pubmed/27402103 http://dx.doi.org/10.1007/s10147-016-1019-4 |